Pharsight

Breo Ellipta is owned by Glaxo Grp Ltd.

Breo Ellipta contains Fluticasone Furoate; Vilanterol Trifenatate.

Breo Ellipta has a total of 10 drug patents out of which 1 drug patent has expired.

Expired drug patents of Breo Ellipta are:

US7776895

Breo Ellipta was authorised for market use on 10 May, 2013.

Breo Ellipta is available in powder;inhalation dosage forms.

Breo Ellipta can be used as indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; long-term, once daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations, indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; for the long-term, once-daily maintenance treatment of airflow obstruction in patients with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations, indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a history of exacerbations; indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older, indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including bronchitis and/or emphysema; indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; indicated for the once-daily treatment of asthma in patients 18 years and older; indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a history of exacerbations.

The generics of Breo Ellipta are possible to be released after 11 October, 2030.

Application	Filing Date	Opposition Party	Legal Status
EP06765149A	2020-04-17	ELKINGTON AND FIFE LLP	Patent maintained as amended
EP09779096A	2020-02-24	SANDOZ AG	Granted and Under Opposition
EP09779096A	2020-02-21	Teva UK Limited	Granted and Under Opposition
EP09779096A	2020-02-21	HGF Limited	Granted and Under Opposition
EP09779096A	2020-02-21	N.V. Nederlandsch Octrooibureau	Granted and Under Opposition
EP09779096A	2020-02-20	Aera A/S	Granted and Under Opposition
EP09779096A	2020-02-20	Gill Jennings & Every LLP	Granted and Under Opposition
EP09779096A	2020-02-18	Dehns Ltd	Granted and Under Opposition
EP09779096A	2020-02-14	Arven Ilac Sanayi Ve Ticaret A.S.	Granted and Under Opposition
EP10178947A	2015-06-24	Teva UK Limited	Revoked
EP03731693A	2014-05-14	Teva UK Limited	Opposition rejected
EP03731693A	2014-05-08	Vossius & Partner	Opposition rejected

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44874	GLAXO GRP LTD	Phenethanolamine derivatives for treatment of respiratory diseases	Mar, 2023 (2 days from now)
US7439393	GLAXO GRP LTD	Phenethanolamine derivatives for treatment of respiratory diseases	May, 2025 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7776895	GLAXO GRP LTD	Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases	Sep, 2022 (6 months ago)
US8511304	GLAXO GRP LTD	Medicament dispenser	Jun, 2027 (4 years from now)
US9333310	GLAXO GRP LTD	Medicament dispenser	Oct, 2027 (4 years from now)
US8113199	GLAXO GRP LTD	Counter for use with a medicament dispenser	Oct, 2027 (4 years from now)
US8161968	GLAXO GRP LTD	Medicament dispenser	Feb, 2028 (4 years from now)
US11116721	GLAXO GRP LTD	Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol	Feb, 2029 (5 years from now)
US8534281	GLAXO GRP LTD	Manifold for use in medicament dispenser	Mar, 2030 (6 years from now)
US8746242	GLAXO GRP LTD	Medicament dispenser	Oct, 2030 (7 years from now)

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; Long-term, once daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations; Indicated for long-term, once-daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in pts with a history of exacerbations; For the long-term, once-daily maintenance treatment of airflow obstruction in patients with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations; Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including bronchitis and/or emphysema; Indicated for the once-daily treatment of asthma in patients 18 years and older

Dosage: POWDER;INHALATION